# An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer

> **NCT00054899** · PHASE1 · COMPLETED · sponsor: **Epimmune** · enrollment: 18 (—)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasm

## Interventions

- **BIOLOGICAL:** EP2101

## Key facts

- **NCT ID:** NCT00054899
- **Lead sponsor:** Epimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 18 (—)
- **Last updated:** 2010-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00054899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00054899, "An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00054899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*